Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL95278 | 0.88 | CHRM2 (0.33) | CHRM2CHRM1CHRNB2CHRM3CHRNA4 | |
| SCHEMBL3027266 | 0.88 | CHRM2 (0.34) | CHRM2CHRM1CHRNB2CHRM3CHRNA4 | |
| SCHEMBL11044069 | 0.87 | KCNH2 (0.34) | CHRM2CHRM1CHRNB2CHRM3CHRNA4 | |
| SCHEMBL27517885 | 0.84 | CHRM2 (0.46) | CHRM2CHRM1CHRNB2CHRM3CHRNA4 | |
| SCHEMBL9335503 | 0.82 | CHRM2 (0.34) | CHRM2CHRM1CHRNB2CHRM3CHRNA4 | |
| SCHEMBL9339240 | 0.81 | KCNH2 (0.34) | CHRM2CHRM1CHRNB2CHRM3CHRNA4 | |
| SCHEMBL11519567 | 0.81 | KCNH2 (0.34) | CHRM2CHRM1CHRNB2CHRM3CHRNA4 | |
| SCHEMBL10753596 | 0.81 | CHRM2 (0.33) | CHRM2CHRM1CHRNB2CHRM3CHRNA4 | |
| SCHEMBL6979656 | 0.80 | TAAR1 (0.33) | CHRM2CHRM1CHRNB2CHRM3CHRNA4 | |
| SCHEMBL9335726 | 0.78 | KCNH2 (0.32) | CHRM2CHRM1CHRNB2CHRM3CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1957073-B1 | MEDICINAL DRUG | OTSUKA PHARMA CO LTD (JP) | 2014-04-23 | — | — | EP | disclosed |
| US-8551999-B2 | Heterocyclic compound and pharmaceutical composition thereof | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-10-08 | — | — | US | disclosed |
| EP-2612858-A1 | STAT3/5 activation inhibitor | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-07-10 | — | — | EP | disclosed |
| US-20120322807-A1 | STAT3/5 ACTIVATION INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. | 2012-12-20 | — | — | US | disclosed |
| US-20120238750-A1 | AROMATIC COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. | 2012-09-20 | — | — | US | disclosed |
| US-8263599-B2 | STAT3/5 activation inhibitor | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-09-11 | — | — | US | disclosed |
| US-8236826-B2 | Diarylether derivatives as antitumor agents | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-08-07 | — | — | US | disclosed |
| EP-2207773-B1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF | OTSUKA PHARMA CO LTD (JP) | 2012-07-11 | — | — | EP | disclosed |
| US-8188277-B2 | Aromatic compounds for suppressing the generation of collagen | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-05-29 | — | — | US | disclosed |
| US-20100261720-A1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-10-14 | — | — | US | disclosed |
| EP-1773797-A2 | AROMATIC COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006014012-A2 | AROMATIC COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-02-09 | — | — | WO | disclosed |
| EP-0323441-B1 | 5-Fluorouracil derivatives | OTSUKA PHARMA CO LTD (JP) | 1996-04-24 | — | — | EP | disclosed |
| US-5155113-A | Administering 5-fluorouracil and derivatives with pyridine and pyridone derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1992-10-13 | — | — | US | disclosed |
| EP-0180188-B1 | A COMPOSITION FOR INCREASING THE ANTI-CANCER ACTIVITY OF AN ANTI-CANCER COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1992-04-15 | — | — | EP | disclosed |
| US-4983609-A | Anticancer agents | OTSUKA PHARMACEUTICAL (JP) | 1991-01-08 | — | — | US | disclosed |
| US-4864021-A | ANTICARCINOGENIC AGENTS, ANTITUMOR AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1989-09-05 | — | — | US | disclosed |
| EP-0323441-A2 | 5-Fluorouracil derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1989-07-05 | — | — | EP | disclosed |
| EP-0180897-A2 | 5-Fluorouracil derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-05-14 | — | — | EP | disclosed |
| EP-0180188-A2 | A composition for increasing the anti-cancer activity of an anti-cancer compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261720-A1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF | COL1A1, COL2A1, COL14A1 | CHRM2 173/4885CHRM1 51/4885CHRNB2 1647/4885 |
| US-20120238750-A1 | AROMATIC COMPOUND | CBR1, CBR3, CYP1A1 | CHRM2 89/4885CHRM1 9/4885CHRNB2 2056/4885 |
| US-20120322807-A1 | STAT3/5 ACTIVATION INHIBITOR | STAT3, JAK2, STAT1 | CHRM2 4328/4885CHRM1 3455/4885CHRNB2 4725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.